Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Dasatinib Added to Aromatase Inhibitor Extends PFS in HER2-Negative MBC - See more at: http://www.onclive.com/conference-coverag

December 18, 2013

By Onc Live

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled progression-free survival (PFS) compared with letrozole alone in women with hormone receptor-positive, HER2-negative metastatic breast cancer. The PFS endpoint was an exploratory secondary endpoint of a phase II noncomparative clinical trial presented at the 2013 San Antonio Breast Cancer Symposium.
- See more at: http://www.onclive.com/conference-coverage/sabcs-2013/Dasatinib-Added-to-Aromatase-Inhibitor-Extends-PFS-in-HER2-Negative-MBC?utm_source=Informz&utm_medium=OncLive&utm_campaign=SABCS%20(Faslodex)%2012-13-13#sthash.wZLyUTRF.dpuf

Dasatinib may inhibit AI resistance in metastatic breast cancer

December 14, 2013

By Healio

Dasatinib inhibited aromatase inhibitor resistance in postmenopausal women with locally recurrent or metastatic breast cancer, according to results of a small phase 2 study presented at the San Antonio Breast Cancer Symposium.

Subgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2

November 26, 2013

By Onc Live

New analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival (PFS) than placebo and exemestane in several previously unstudied patient subgroups. The data were presented at the 2013 Breast Cancer Symposium.

Novartis chases Pfizer in hot new breast cancer drug area

November 22, 2013

By Reuters

The significance of the new targeted approach to fighting cancer was highlighted in April when U.S. regulators granted a "breakthrough therapy" designation to palbociclib, based on impressive results seen in mid-stage trials.

Penn Study Identifies New Trigger for Breast Cancer Metastasis

November 6, 2013

Researchers have revealed how a reduction in mitochondrial DNA content leads human breast cancer cells to take on aggressive, metastatic properties.

Managing mTOR Inhibitor Side Effects in Breast Cancer

November 5, 2013

By OncLive

Last year the FDA approved everolimus for the treatment of HR-positive, HER2-negative breast cancer, when given in combination with the aromatase inhibitor (AI) exemestane, in previously treated postmenopausal women, based on findings of the BOLERO-2 trial.

Pfizer Pharmaceutical launches global breast cancer clinical trial at Southern Cancer Center

November 4, 2013

Specifically, the study will evaluate palbociclib in combination with fulvestrant in women with hormone positive, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy.

ASCO Issues β€˜Top 5’ List of Overused Cancer Tests and Treatments

October 31, 2013

By CancerNetwork

The American Society of Clinical Oncology (ASCO) today issued its second "Top 5" list of tests and treatments that are routinely used by oncologists despite a lack of evidence that they are cost effective or beneficial to patients.

US Oncology inks pact with BioMarin Pharma to launch PARP inhibitor phase III study in BRCA metastatic breast cancer patients

October 28, 2013

US Oncology Research to offer a groundbreaking phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients who test positive for BRCA1 or BRCA2 gene mutations.

Seattle Genetics Initiates Phase 1 Trial of ADC Candidate, SGN-LIV1A,

October 27, 2013

The target expression in breast cancer, preclinical antitumor activity, and need for novel therapeutic options for advanced breast cancer patients all support the clinical evaluation of SGN-LIV1A.

‹ First  < 2 3 4 5 6 >  Last ›